Where is Hayfin's headquarters located?

Hayfin's headquarters is located in London (United Kingdom).

How many companies has Hayfin invested in?

Hayfin has invested in 11 companies, including HeartFlow & Xeris Pharmaceuticals.

Which companies has Hayfin invested in lately?

Glytec & HeartFlow are the latest investments by Hayfin.

What sectors does Hayfin focus on for investments?

Top sectors in Hayfin's portfolio are Life Sciences (6 investments) and HealthTech (3 investments).

How many exits has Hayfin been involved in?

Hayfin's portfolio has seen 3 IPOs and 2 acquisitions.

Hayfin - 2026 Investor Profile, Portfolio & Investment Trends

1. HeartFlow

HeartFlow provides cardiovascular diagnostic support using analytics. The company's technology uses CT scans and high-performance computing to provide physicians with data about blood flow within the coronary arteries. The company claims that the HeartFlow technology analysis led to the improvement in diagnostic accuracy as compared to a standard CT scan.

Key facts about HeartFlow

Founded Year: 2007
Location: Redwood City (United States)
Stage: Public
Total Funding till date: $936M
Employee Count: 891 as on Sep 30, 2026
Investors: Section Partners, SeedFord Partners and 25 Others
Latest Funding Round: Series F, Mar 27, 2025, $*****
Highlight: Public

2. Xeris Pharmaceuticals

Developer of liquid-stable injectables for the delivery of drugs. The company is developing a stable, ready-to-inject glucagon formulation "Gvoke" which is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes. The company has developed proprietary formulation technologies such as XeriSol and XeriJect which are currently being evaluated for subcutaneous and intramuscular delivery of highly-concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, and antibodies.

Key facts about Xeris Pharmaceuticals

Founded Year: 2005
Location: Chicago (United States)
Annual Revenue: $100M - $500M as on Dec 31, 2025
Stage: Public
Total Funding till date: $155M
Employee Count: 532 as on Sep 30, 2026
Investors: Armistice Capital, Longitude Capital and 19 Others
Latest Funding Round: Post IPO, Jan 02, 2022, $*****
Highlight: Public

3. MolecuLight

Provider of point of care device for wound assessment. The company's first product, the i:X, is a hand-held fluorescence imaging device for visualizing bacterial presence and distribution in the skin and chronic wounds. i:X launched in 2015. Founded by Dr. Ralph Da Costa.

Key facts about MolecuLight

Founded Year: 2013
Location: Toronto (Canada)
Stage: Series D
Total Funding till date: $43.2M
Employee Count: 49 as on May 27, 2025
Investors: SWK Holdings, MaRS Discovery District and 7 Others
Latest Funding Round: Series D, Jan 06, 2025, $*****
Highlight: Editors' Pick

4. Glytec

Cloud based platform for diabetes and insulin management. It aiming to enhance patient outcomes and simplify glycemic management for healthcare providers. The platform offers decision support tools and insulin dosing software to provide collaborative care. It provides product suite such as glytec command center, glucommander subQ, glytec analytics, and glucommander IV.

Key facts about Glytec

Founded Year: 2005
Location: United States
Stage: Series C
Total Funding till date: $56.3M
Employee Count: 81 as on Sep 30, 2026
Investors: SVB, Hayfin and 1 Other
Latest Funding Round: Series C, Jun 18, 2025, $*****
Highlight: Editors' Pick

5. GC Aesthetics

Manufacturer of silicone breast implants for aesthetic and reconstructive surgery. These medical devices are designed for use in breast augmentation and total breast reconstruction procedures. The product line includes various shapes and sizes to address individual patient requirements. The business provides information regarding surgical procedures, recovery, and post-operative care to assist patients and medical professionals. Additionally, the entity offers a warranty program covering its implant products.

Key facts about GC Aesthetics

Founded Year: 2007
Location: Dublin (Ireland)
Annual Revenue: $50M - $100M as on Dec 31, 2018
Valuation: $*****
Stage: Series E
Total Funding till date: $233M
Employee Count: 203 as on Jun 30, 2026
Investors: Hayfin, Orbimed and 18 Others
Latest Funding Round: Series E, Oct 29, 2018, $*****
Highlight: Editors' Pick

View the full list of portfolio companies

Hayfin has invested in 14 companies over the last 11 years, with an average of 1 new investment annually in the last 10 years. In 2025, it made 3 investments. Its most recent first time investment was in Glytec and most recent follow-on round was in HeartFlow.

Here are Hayfin's Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2026 (YTD)	0	0	0
2025	2	1	3
2024	0	0	0
2023	1	0	1
2022	2	1	3
2021	0	0	0
2020	1	0	1
2019	0	0	0
2018	4	0	4

View all investments by Hayfin

Hayfin has made 6 investments in Conventional Debt stage with an average round size of $37M, 2 investments in Post IPO stage with an average round size of $100M, 1 investment in Series C stage with an average round size of $36M, 1 investment in Series D stage with an average round size of $27.5M and 1 investment in Series F stage with an average round size of $216M.

Here are Hayfin's investments by stage:

Stage of entry	No. of Investments
Conventional Debt	6
Post IPO	2
Series C	1
Series D	1
Series F	1

Note: We have considered here, only first round of investments

View all investments by Hayfin

Hayfin has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Healthcare, Enterprise Applications and Vertical SaaS. Notably, it has invested in 9 Enterprise (B2B) companies, 9 Tech companies, 4 Consumer (B2C) companies and at least 3 companies focusing on Tech hardware.

Here are Hayfin's investments by sector:

Sector	No. of Investments
Life Sciences	6
HealthTech	3
Healthcare	3
Enterprise Applications	2
Vertical SaaS	2
Others	3

Note: We have considered here, only first round of investments

View all investments by Hayfin

Hayfin has made most investments in United States (8), followed by Canada where it has made 1 investment.

Here are Hayfin's investments by geography:

Country	No. of Investments
United States	8
Canada	1
Ireland	1
United Kingdom	1

Note: We have considered here, only first round of investments

View all investments by Hayfin

Hayfin has not made any investment in 2026 so far.

Here are the most recent investments by Hayfin:

Filter this list

Date	Company	Location	Round Details	Round Amount	Co-Investors
Jun 18, 2025	Glytec	United States	Series C	2470	Savitr Capital
Mar 27, 2025	HeartFlow	United States	Series F	4923	Fidelity Investments [+6]
Jan 06, 2025	MolecuLight	Canada	Series D	5630	-
Mar 02, 2023	HeartFlow	United States	Series F	2441	Bain Capital Life Sciences ... [+7]
Jun 14, 2022	KEO World	United States	Series B	7398	Montreux Equity Partners [+2]

See more recent investments made by Hayfin

3 of Hayfin's portfolio companies have become public. HeartFlow got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2025 at marketcap of $1.53B and Xeris Pharmaceuticals got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).

Here are Hayfin's portfolio companies that went public:

Filter this list

Company	IPO Date	First Invested on	First Round of Investment	Round Size
HeartFlow	Aug 08, 2025	Mar 02, 2023	Series F	7184
Xeris Pharmaceuticals	Jun 21, 2018	Jan 02, 2022	Post IPO	2841
MiMedx Group	Sep 04, 2007	Jul 02, 2020	Post IPO	3868

View more details about public companies in Hayfin's portfolio

2 companies from Hayfin's portfolio have been acquired. The most recent acquisition was Sinclair in Nov 2018 by Huadong Medicine for $*****.

Here are Hayfin's portfolio companies that got acquired most recently:

Filter this list

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
Sinclair	Nov 19, 2018	Apr 30, 2018	Conventional Debt	2593
Crown Laboratories	Oct 30, 2017	Sep 2015	Conventional Debt	8657

View all acquired companies in Hayfin's portfolio

Over the past 11 years, 60 investors have co-invested in Hayfin's portfolio companies. This includes funds and angels.

Invested before Hayfin: HHS, HealthCor Partners and 48 others have invested in rounds before Hayfin. There are 2 companies where HHS has invested before Hayfin and 1 company where HealthCor Partners has invested before Hayfin.
Top Co-investors of Hayfin: 4 investors entered a company along with Hayfin. These include investors like Bain Capital Life Sciences (1 company).
Invested after Hayfin: A total of 6 investors have invested in Hayfin's portfolio after their investments. Top Investors include Montreux Equity Partners (2 companies) and Fidelity Investments (1 company).